{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:39:22Z","timestamp":1793036362815,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10147-026-03196-8","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:53:09Z","timestamp":1789638789000},"page":"2812-2822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical activity of platinum rechallenge with nedaplatin plus irinotecan in recurrent cervical cancer following prior platinum-based systemic chemotherapy: a single-center retrospective study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3319-1205","authenticated-orcid":false,"given":"Yoshifumi","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miku","family":"Takadera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Ogawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Suizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Koyanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyo","family":"Taneichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Saga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"key":"3196_CR1","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1186\/s12889-019-7097-2","volume":"19","author":"T Okuhara","year":"2019","unstructured":"Okuhara T, Ishikawa H, Okada M, Kato M, Kiuchi T (2019) Newspaper coverage before and after the HPV vaccination crisis began in Japan: a text mining analysis. BMC Public Health 19:770. https:\/\/doi.org\/10.1186\/s12889-019-7097-2","journal-title":"BMC Public Health"},{"key":"3196_CR2","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2004.04.170","volume":"22","author":"DH Moore","year":"2004","unstructured":"Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, Miller DS, Olt G, King S, Boggess JF, Rocereto TF (2004) Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 22:3113\u20133119. https:\/\/doi.org\/10.1200\/JCO.2004.04.170","journal-title":"J Clin Oncol"},{"key":"3196_CR3","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","volume":"27","author":"BJ Monk","year":"2009","unstructured":"Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D (2009) Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 27:4649\u20134655. https:\/\/doi.org\/10.1200\/JCO.2009.21.8909","journal-title":"J Clin Oncol"},{"key":"3196_CR4","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","volume":"33","author":"R Kitagawa","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T, Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, Nishimura S, Ushijima K, Takano M, Satoh T, Yoshikawa H (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 33:2129\u20132135. https:\/\/doi.org\/10.1200\/JCO.2014.58.4391","journal-title":"J Clin Oncol"},{"key":"3196_CR5","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ (2014) Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 370:734\u2013743. https:\/\/doi.org\/10.1056\/NEJMoa1309748","journal-title":"N Engl J Med"},{"key":"3196_CR6","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","volume":"390","author":"KS Tewari","year":"2017","unstructured":"Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ (2017) Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet 390:1654\u20131663. https:\/\/doi.org\/10.1016\/S0140-6736(17)31607-0","journal-title":"Lancet"},{"key":"3196_CR7","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","volume":"385","author":"N Colombo","year":"2021","unstructured":"Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, Tewari KS, Salman P, Hoyos Usta E, Ya\u00f1ez E, G\u00fcm\u00fc\u015f M, Olivera Hurtado de Mendoza M, Samou\u00eblian V, Castonguay V, Arkhipov A, Toker S, Li K, Keefe SM, Monk BJ, KEYNOTE-826 Investigators (2021) Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med 385:1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa2112435","journal-title":"N Engl J Med"},{"key":"3196_CR8","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1200\/JCO.23.00914","volume":"41","author":"BJ Monk","year":"2023","unstructured":"Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Ya\u00f1ez E, G\u00fcm\u00fc\u015f M, Olivera Hurtado de Mendoza M, Samou\u00eblian V, Castonguay V, Arkhipov A, Tekin C, Li K, Keefe SM, Lorusso D, KEYNOTE-826 Investigators (2023) First-line pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Final overall survival results of KEYNOTE-826. J Clin Oncol 41:5505\u20135511. https:\/\/doi.org\/10.1200\/JCO.23.00914","journal-title":"J Clin Oncol"},{"key":"3196_CR9","doi-asserted-by":"publisher","first-page":"115146","DOI":"10.1016\/j.ejca.2024.115146","volume":"216","author":"A Oaknin","year":"2025","unstructured":"Oaknin A, Monk BJ, de Melo AC, Kim HS, Kim YM, Lisyanskaya AS, Samou\u00eblian V, Lorusso D, Damian F, Chang CL, Gotovkin E, Takahashi S, Ramone D, Ma\u0107kowiak-Matejczyk B, Polastro L, Alia EMG, Colombo N, Makarova Y, Goh JC, Hasegawa K, Mora P, Pikiel J, Srivastav R, Rischin D, Rubio MJ, Perez J, Yoo SY, Gao B, Jamil S, Seebach F, Lowy I, Mathias M, Fury MG, Tewari KS (2025) Cemiplimab in recurrent cervical cancer: final analysis of overall survival in the phase III EMPOWER-Cervical 1\/GOG-3016\/ENGOT-cx9 trial. Eur J Cancer 216:115146. https:\/\/doi.org\/10.1016\/j.ejca.2024.115146","journal-title":"Eur J Cancer"},{"key":"3196_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","volume":"22","author":"RL Coleman","year":"2021","unstructured":"Coleman RL, Lorusso D, Gennigens C, Gonz\u00e1lez-Mart\u00edn A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindel\u00f8v SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I (2021) Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22:609\u2013619. https:\/\/doi.org\/10.1016\/S1470-2045(21)00056-5. innovaTV 204\/GOG-3023\/ENGOT-cx6 Collaborators","journal-title":"Lancet Oncol"},{"key":"3196_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2313811","volume":"391","author":"I Vergote","year":"2024","unstructured":"Vergote I, Gonz\u00e1lez-Mart\u00edn A, Fujiwara K, Kalbacher E, Bagam\u00e9ri A, Ghamande S, Lee JY, Banerjee S, Maluf FC, Lorusso D, Yonemori K, Van Nieuwenhuysen E, Manso L, Woelber L, Westermann A, Covens A, Hasegawa K, Kim BG, Raimondo M, Bjurberg M, Cruz FM, Angelergues A, Cibula D, Barraclough L, Oaknin A, Gennigens C, Nicacio L, Teng MSL, Whalley E, Soumaoro I, Slomovitz BM; innovaTV 301\/ENGOT-cx12\/GOG-3057 Collaborators (2024) Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer. N Engl J Med 391:44\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2313811","journal-title":"N Engl J Med"},{"key":"3196_CR12","first-page":"695","volume":"19","author":"T Kato","year":"1992","unstructured":"Kato T, Nishimura H, Yakushiji M, Noda K, Terashima Y, Takeuchi S, Takamizawa H, Suzuki M, Arai M, Ota M et al (1992) Phase II study of 254-S (cis-diammine glycolato platinum) for gynecological cancer. Gan Kagaku Ryoho 19:695\u2013701 [in Japanese]","journal-title":"Gan Kagaku Ryoho"},{"key":"3196_CR13","first-page":"1681","volume":"18","author":"S Takeuchi","year":"1991","unstructured":"Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamaya T et al (1991) A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Gan Kagaku Ryoho 18:1681\u20131689 [in Japanese]","journal-title":"Gan Kagaku Ryoho"},{"key":"3196_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1200\/JCO.1997.15.2.625","volume":"15","author":"CF Verschraegen","year":"1997","unstructured":"Verschraegen CF, Levy T, Kudelka AP, Llerena E, Ende K, Freedman RS, Edwards CL, Hord M, Steger M, Kaplan AL, Kieback D, Fishman A, Kavanagh JJ (1997) Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15:625\u2013631. https:\/\/doi.org\/10.1200\/JCO.1997.15.2.625","journal-title":"J Clin Oncol"},{"key":"3196_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/(SICI)1097-0142(19980115)82:2<334::AID-CNCR13>3.0.CO;2-#","volume":"82","author":"WP Irvin","year":"1998","unstructured":"Irvin WP, Price FV, Bailey H, Gelder M, Rosenbluth R, Durivage HJ, Potkul RK (1998) A phase II study of irinotecan (CPT-11) in patients with advanced squamous cell carcinoma of the cervix. Cancer 82:328\u2013333","journal-title":"Cancer"},{"key":"3196_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000012076","volume":"58","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama T, Yakushiji M, Noda K, Ikeda M, Kudoh R, Yajima A, Tomoda Y, Terashima Y, Takeuchi S, Hiura M, Saji F, Takahashi T, Umesaki N, Sato S, Hatae M, Ohashi Y (2000) Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58:31\u201337. https:\/\/doi.org\/10.1159\/000012076","journal-title":"Oncology"},{"key":"3196_CR17","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/sj.bjc.6602076","volume":"91","author":"H Tsuda","year":"2004","unstructured":"Tsuda H, Hashiguchi Y, Nishimura S, Miyama M, Nakata S, Kawamura N, Negoro S (2004) Phase I-II study of irinotecan (CPT-11) plus nedaplatin (254-S) with recombinant human granulocyte colony-stimulating factor support in patients with advanced or recurrent cervical cancer. Br J Cancer 91:1032\u20131037. https:\/\/doi.org\/10.1038\/sj.bjc.6602076","journal-title":"Br J Cancer"},{"key":"3196_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s10147-012-0487-4","volume":"18","author":"T Ohara","year":"2013","unstructured":"Ohara T, Kobayashi Y, Yoshida A, Yoshioka N, Yahagi N, Kondo H, Tozawa A, Kiguchi K, Suzuki N (2013) Combination of irinotecan (CPT-11) and nedaplatin (NDP) for recurrent patients with uterine cervical cancer. Int J Clin Oncol 18:1102\u20131106. https:\/\/doi.org\/10.1007\/s10147-012-0487-4","journal-title":"Int J Clin Oncol"},{"key":"3196_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"3196_CR20","unstructured":"National Cancer Institute Common terminology criteria for adverse events, version 5.0. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events. Accessed 12 May 2026"},{"key":"3196_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software EZR for medical statistics. Bone Marrow Transpl 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transpl"},{"key":"3196_CR22","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1159\/000072333","volume":"65","author":"S Machida","year":"2003","unstructured":"Machida S, Ohwada M, Fujiwara H, Konno R, Takano M, Kita T, Kikuchi Y, Komiyama S, Mikami M, Suzuki M (2003) Phase I study of combination chemotherapy using irinotecan hydrochloride and nedaplatin for advanced or recurrent cervical cancer. Oncology 65:102\u2013107. https:\/\/doi.org\/10.1159\/000072333","journal-title":"Oncology"},{"key":"3196_CR23","doi-asserted-by":"publisher","unstructured":"Gonz\u00e1lez-Mart\u00edn A, Harter P, Leary A, Lorusso D, Miller RE, Pothuri B, Ray-Coquard I, Tan DSP, Bellet E, Oaknin A, Ledermann JA ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2023) Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 34:833\u2013848. https:\/\/doi.org\/10.1016\/j.annonc.2023.07.011","DOI":"10.1016\/j.annonc.2023.07.011"},{"key":"3196_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00280-017-3402-x","volume":"80","author":"M Takekuma","year":"2017","unstructured":"Takekuma M, Mori K, Iida T, Kurihara K, Saitou M, Tokunaga H, Kawana K, Ikeda M, Satoh T, Saito T, Miyagi E, Nagai Y, Furusawa A, Kawano Y, Kawano K, Tabata T, Ota Y, Hayase R, Mikami M, Sugiyama T (2017) The concept of platinum sensitivity could be applied to recurrent cervical cancer: A multi-institutional retrospective study from the Japanese Gynecologic Oncology Group. Cancer Chemother Pharmacol 80:697\u2013705. https:\/\/doi.org\/10.1007\/s00280-017-3402-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"3196_CR25","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1097\/IGC.0b013e3182a80a07","volume":"23","author":"M Matoda","year":"2013","unstructured":"Matoda M, Tanigawa T, Omatsu K, Ushioda N, Yamamoto A, Okamoto S, Kawamata Y, Kato K, Umayahara K, Takeshima N (2013) Platinum-free interval in second-line chemotherapy for recurrent cervical cancer. Int J Gynecol Cancer 23:1670\u20131674. https:\/\/doi.org\/10.1097\/IGC.0b013e3182a80a07","journal-title":"Int J Gynecol Cancer"},{"key":"3196_CR26","first-page":"6921","volume":"60","author":"Y Ando","year":"2000","unstructured":"Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921\u20136926","journal-title":"Cancer Res"},{"key":"3196_CR27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/FPC.0b013e328014341f","volume":"17","author":"H Minami","year":"2007","unstructured":"Minami H, Sai K, Saeki M, Saito Y, Ozawa S, Suzuki K, Kaniwa N, Sawada J, Hamaguchi T, Yamamoto N, Shirao K, Yamada Y, Ohmatsu H, Kubota K, Yoshida T, Ohtsu A, Saijo N (2007) Irinotecan pharmacokinetics\/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genom 17:497\u2013504. https:\/\/doi.org\/10.1097\/FPC.0b013e328014341f","journal-title":"Pharmacogenet Genomics"},{"key":"3196_CR28","doi-asserted-by":"publisher","first-page":"207084","DOI":"10.1155\/2010\/207084","volume":"2010","author":"N Makrilia","year":"2010","unstructured":"Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW (2010) Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs 2010:207084. https:\/\/doi.org\/10.1155\/2010\/207084","journal-title":"Met Based Drugs"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03196-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:03:40Z","timestamp":1793034220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03196-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3196"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03196-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Ethics Committee of Jichi Medical University (Institutional Review Board No. 26\u2013027).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the use of anonymized clinical data, written informed consent from patients was not obtained. Instead, an opt-out method was used through public disclosure of the study information.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}